Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Izar, Benjamin; Sharfman, William; Hodi, F Stephen; Lawrence, Donald; Flaherty, Keith T; Amaravadi, Ravi; Kim, Kevin B; Puzanov, Igor; Sosman, Jeffrey; Dummer, Reinhard; Goldinger, Simone M; Lam, Lyhping; Kakar, Shefali; Tang, Zhongwen; Krieter, Oliver; McDermott, David F; Atkins, Michael B (2017). A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine, 6(8):1904-1914.

Smith, Michael P; Rowling, Emily J; Miskolczi, Zsofia; Ferguson, Jennifer; Spoerri, Loredana; Haass, Nikolas K; Sloss, Olivia; McEntegart, Sophie; Arozarena, Imanol; von Kriegsheim, Alex; Rodriguez, Javier; Brunton, Holly; Kmarashev, Jivko; Levesque, Mitchell P; Dummer, Reinhard; Frederick, Dennie T; Andrews, Miles C; Cooper, Zachary A; Flaherty, Keith T; Wargo, Jennifer A; Wellbrock, Claudia (2017). Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 9(8):1011-1029.

Smith, Michael P; Brunton, Holly; Rowling, Emily J; Ferguson, Jennifer; Arozarena, Imanol; Miskolczi, Zsofia; Lee, Jessica L; Girotti, Maria R; Marais, Richard; Levesque, Mitchell P; Dummer, Reinhard; Frederick, Dennie T; Flaherty, Keith T; Cooper, Zachary A; Wargo, Jennifer A; Wellbrock, Claudia (2016). Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell, 29(3):270-84.

Merlino, Glenn; Herlyn, Meenhard; Fisher, David E; Bastian, Boris C; Flaherty, Keith T; Davies, Michael A; Wargo, Jennifer A; Curiel-Lewandrowski, Clara; Weber, Michael J; Leachman, Sancy A; Soengas, Maria S; McMahon, Martin; Harbour, J. William; Swetter, Susan M; Aplin, Andrew E; Atkins, Michael B; Bosenberg, Marcus W; Dummer, Reinhard; Gershenwald, Jeffrey E; Halpern, Allan C; Herlyn, Dorothee; Karakousis, Giorgos C; Kirkwood, John M; Krauthammer, Michael; Lo, Roger S; Long, Georgina V; McArthur, Grant; Ribas, Antoni; Schuchter, Lynn; Sosman, Jeffrey A; Smalley, Keiran S; Steeg, Patricia; Thomas, Nancy E; Tsao, Hensin; Tueting, Thomas; Weeraratna, Ashani; Xu, George; Lomax, Randy; Martin, Alison; Silverstein, Steve; Turnham, Tim; Ronai, Ze'ev A (2016). The state of melanoma: challenges and opportunities. Pigment Cell & Melanoma Research, 29(4):404-416.

Kleffel, Sonja; Posch, Christian; Barthel, Steven R; Mueller, Hansgeorg; Schlapbach, Christoph; Guenova, Emmanuella; Elco, Christopher P; Lee, Nayoung; Juneja, Vikram R; Zhan, Qian; Lian, Christine G; Thomi, Rahel; Hoetzenecker, Wolfram; Cozzio, Antonio; Dummer, Reinhard; Mihm, Martin C; Flaherty, Keith T; Frank, Markus H; Murphy, George F; Sharpe, Arlene H; Kupper, Thomas S; Schatton, Tobias (2015). Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell, 162(6):1242-1256.

Kim, Hyungsoo; Frederick, Dennie T; Levesque, Mitchell P; Cooper, Zachary A; Feng, Yongmei; Krepler, Clemens; Brill, Laurence; Samuels, Yardena; Hayward, Nicholas K; Perlina, Ally; Piris, Adriano; Zhang, Tongwu; Halaban, Ruth; Herlyn, Meenhard M; Brown, Kevin M; Wargo, Jennifer A; Dummer, Reinhard; Flaherty, Keith T; Ronai, Ze'ev A (2015). Downregulation of the ubiquitin ligase RNF125 underlies resistance of melanoma cells to BRAF inhibitors via JAK1 deregulation. Cell Reports, 11(9):1458-1473.

Lorigan, Paul; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M; Flaherty, Keith T; Garbe, Claus; Gogas, Helen; Hauschild, Axel; Kefford, Richard F; Kirkwood, John M; Larkin, James; Long, Georgina V; Maio, Michele; McArthur, Grant A; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Sondak, Vernon K; Wolchok, Jedd D; Hudson, Andrew M (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, 16(1):15-17.

McArthur, Grant A; Chapman, Paul B; Robert, Caroline; Larkin, James; Haanen, John B; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbé, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J; Kirkwood, John M; Eggermont, Alexander M; Dréno, Brigitte; Sosman, Jeffrey A; Flaherty, Keith T; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, 15(3):323-332.

Flaherty, Keith T; Hennig, Michael; Lee, Sandra J; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M M; Hauschild, Axel; Kefford, Richard; Kirkwood, John M; Long, Georgina V; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant; O'Day, Steven; Patel, Poulam M; Robert, Caroline; Schadendorf, Dirk (2014). Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, 15(3):297-304.

Dummer, Reinhard; Flaherty, Keith T (2012). Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Current Opinion in Oncology, 24(2):150-154.

This list was generated on Sat Nov 18 03:22:45 2017 CET.